| Literature DB >> 28980030 |
M Koch1, K Utpatel2, C Schulz3.
Abstract
The case of a 58-year old female patient with epidermal growth factor-positive pulmonary adenocarcinoma treated with the tyrosine kinase inhibitor afatinib is reported. After several months of first-line therapy the patient developed severe hyponatremia and tumor reassessment revealed a progressive course of the lung cancer. Rebiopsy showed transformation of the tumor into small-cell lung cancer. Therapy with afatinib was stopped immediately and platin-based chemotherapy was started. This case shows that tumor transformation under tyrosine kinase inhibitor therapy from non-small-cell into small-cell lung cancer can occur in rare cases.Entities:
Keywords: Afatinib; Biopsy; Non-small-cell lung cancer; Small-cell lung cancer; Tyrosine kinase inhibitor
Mesh:
Substances:
Year: 2018 PMID: 28980030 DOI: 10.1007/s00108-017-0321-1
Source DB: PubMed Journal: Internist (Berl) ISSN: 0020-9554 Impact factor: 0.743